{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:28:04Z","timestamp":1786123684920,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pharmthera.2026.109071","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:46:42Z","timestamp":1783061202000},"page":"109071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nipocalimab and other FcRn blockers in neuromuscular disorders"],"prefix":"10.1016","volume":"286","author":[{"given":"Mohamed","family":"Khateb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.pharmthera.2026.109071_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","article-title":"FcRn inhibitor therapies in neurologic diseases","volume":"38","author":"Alfaidi","year":"2024","journal-title":"CNS Drugs"},{"issue":"23 Suppl 2","key":"10.1016\/j.pharmthera.2026.109071_bb0010","first-page":"S40","article-title":"Safety, efficacy, and pharmacokinetics of ARGX-117 in adults with multifocal motor neuropathy: A global, multicenter, placebo-controlled phase 2 study (ARDA)","volume":"99","author":"Allen","year":"2022","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109071_bb0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): A multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"The Lancet Neurology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109071_bb0020","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: Clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nature Reviews Rheumatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109071_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11091446","article-title":"Vaccination in the era of immunosuppression","volume":"11","author":"Alnaimat","year":"2023","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109071_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","article-title":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","volume":"18","author":"Anquetil","year":"2019","journal-title":"Autoimmunity Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109071_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: Results from the randomized phase 2 VIVACITY-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109071_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (VIVACITY-MG3): A phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109071_bb0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/19420862.2018.1462429","article-title":"Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach","volume":"10","author":"Betts","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109071_bb0055","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: A phase 2 randomized controlled trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109071_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"The Lancet Neurology"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109071_bb0065","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1212\/WNL.0b013e3181ff94c2","article-title":"Multifocal motor neuropathy: Association of anti-GM1 IgM antibodies with clinical features","volume":"75","author":"Cats","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0070","series-title":"Fc receptors","first-page":"249","article-title":"FcRn: From molecular interactions to regulation of IgG pharmacokinetics and functions","author":"Challa","year":"2014"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109071_bb0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2990.2010.01153.x","article-title":"An update on inflammatory and autoimmune myopathies","volume":"37","author":"Dalakas","year":"2011","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109071_bb0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies","volume":"14","author":"Dalakas","year":"2021","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0090","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-HMGCR autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Research & Therapy"},{"issue":"17 Suppl 2","key":"10.1016\/j.pharmthera.2026.109071_bb0095","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1212\/WNL.0000000000203439","article-title":"A phase 2\/3 placebo-controlled randomized withdrawal study of nipocalimab for CIDP (ARISE)","volume":"100","author":"Ford","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: Practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheumatic Disease Clinics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109071_bb0110","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and response to vaccines in IgG-mediated autoimmune diseases: Pemphigus and generalized myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10928-024-09952-5","article-title":"Translational population target binding model for the anti-FcRn fragment antibody efgartigimod","volume":"52","author":"Hoefman","year":"2025","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"Journal of Neuroimmunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109071_bb0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in generalized myasthenia gravis (ADAPT)","volume":"20","author":"Howard","year":"2021","journal-title":"The Lancet Neurology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109071_bb0130","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"The Lancet Neurology"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109071_bb0135","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109071_bb0140","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalized myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0145","author":"Janssen Research & Development"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109071_bb0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","author":"Kado","year":"2016","journal-title":"Current Opinion in Rheumatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109071_bb0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/13543784.2025.2511177","article-title":"Prospects for multifocal motor neuropathy treatment by complement inhibition","volume":"34","author":"Katzberg","year":"2025","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109071_bb0160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antib9040053","article-title":"Structure, function, and therapeutic use of IgM antibodies","volume":"9","author":"Keyt","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251388019","article-title":"Open-label study of efgartigimod in seronegative myasthenia gravis","volume":"18","author":"Khateb","year":"2025","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nature Reviews Disease Primers"},{"issue":"414","key":"10.1016\/j.pharmthera.2026.109071_bb0175","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109071_bb0180","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/22143602251384098","article-title":"Emerging therapies in idiopathic inflammatory myopathies","volume":"13","author":"Kocyigit","year":"2025","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jns.2017.01.061","article-title":"Immunoglobulin therapy in multifocal motor neuropathy","volume":"375","author":"Kumar","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1302714","article-title":"Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: Results of a phase 1, placebo-controlled study","volume":"18","author":"Leu","year":"2024","journal-title":"Frontiers in Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109071_bb0195","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109071_bb0200","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1097-2765(01)00230-1","article-title":"Crystal structure at 2.8 \u00c5 of an FcRn\/heterodimeric fc complex: Mechanism of pH-dependent binding","volume":"7","author":"Martin","year":"2001","journal-title":"Molecular Cell"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109071_bb0205","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/1750743X.2025.2491295","article-title":"Rozanolixizumab for myasthenia gravis: A breakthrough treatment and future prospects","volume":"17","author":"Matic","year":"2025","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109071_bb0210","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109071_bb0215","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","article-title":"Therapeutic plasma exchange: Complications and management","volume":"23","author":"Mokrzycki","year":"1994","journal-title":"American Journal of Kidney Diseases"},{"issue":"17 Suppl. 2","key":"10.1016\/j.pharmthera.2026.109071_bb0220","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1212\/WNL.0000000000202419","article-title":"Design of a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA) (P10-5.007)","volume":"100","author":"Najem","year":"2023","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109071_bb0225","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109071_bb0230","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: Adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clinical Reviews in Allergy & Immunology"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1560483","article-title":"Efgartigimod combined with steroids for anti-SRP necrotizing myopathy","volume":"16","author":"Peng","year":"2025","journal-title":"Frontiers in Neurology"},{"issue":"S1","key":"10.1016\/j.pharmthera.2026.109071_bb0240","first-page":"S110","article-title":"Rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy: Randomized subject\u2212\/investigator-blind placebo-controlled phase 2a trial","volume":"27","author":"Querol","year":"2022","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"23 Suppl 2","key":"10.1016\/j.pharmthera.2026.109071_bb0245","first-page":"S35","article-title":"Serum autoantibody lowering by nipocalimab correlates with clinical improvement in generalized myasthenia gravis","volume":"99","author":"Ramchandren","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0250","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: Predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clinical and Experimental Immunology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109071_bb0255","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nature Reviews Immunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109071_bb0260","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1524200","article-title":"Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis","volume":"16","author":"Shelly","year":"2025","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1486659","article-title":"Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation","volume":"15","author":"Shi","year":"2024","journal-title":"Frontiers in Neurology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109071_bb0275","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"mAbs"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109071_bb0280","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109071_bb0285","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1083\/jcb.200809122","article-title":"IgG transport by FcRn","volume":"185","author":"Tzaban","year":"2009","journal-title":"Journal of Cell Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109071_bb0290","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109071_bb0295","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nature Biotechnology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109071_bb0300","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41584-023-00992-8","article-title":"Effect of DMARDs on the immunogenicity of vaccines","volume":"19","author":"Van Sleen","year":"2023","journal-title":"Nature Reviews Rheumatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109071_bb0305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13317-014-0062-2","article-title":"Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis","volume":"5","author":"Vattemi","year":"2014","journal-title":"Autoimmunity Highlights"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneurol.2011.175","article-title":"Multifocal motor neuropathy: Diagnosis, pathogenesis and treatment strategies","volume":"8","author":"Vlam","year":"2012","journal-title":"Nature Reviews Neurology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109071_bb0315","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109071_bb0320","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2470542","article-title":"Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models","volume":"21","author":"Warang","year":"2025","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking","volume":"430","author":"Wolfe","year":"2021","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109071_bb0330","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: A double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurology and Therapy"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0335","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","volume":"15","author":"Yang","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109071_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495415","article-title":"Rapid improvement of anti-HMGCR necrotizing myopathy treated with efgartigimod","volume":"15","author":"Zeng","year":"2024","journal-title":"Frontiers in Immunology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:06Z","timestamp":1786119306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":68,"alternative-id":["S0163725826000987"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109071","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nipocalimab and other FcRn blockers in neuromuscular disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109071"}}